Full Press Release Details
EIP Pharma to Host KOL Breakfast Briefing on Potential of Neflamapimod in Alzheimer's Disease and Dementia with Lewy Bodies.
CRVO
EIP Pharma to Host KOL Breakfast Briefing on Potential of Neflamapimod in Alzheimer's Disease and Dementia with Lewy Bodies
Key Takeaway: EIP Pharma to Host KOL Breakfast Briefing on Potential of Neflamapimod in Alzheimer's Disease and Dementia with Lewy Bodies
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke